Anthem Biosciences IPO Subscribed 3.48x on Day 2; Check GMP And Other Details – Should You Apply?

The Rs 3,395 crore Initial Public Offering (IPO) of Anthem Biosciences, the Bangalore-based contract research, development, and manufacturing organisation (CRDMO has seen strong investor interest, getting subscribed 3.48x times on Day 2 of bidding. This shows a positive response from the market ahead of the issue closing on July 16, 2025.

Anthem Biosciences IPO opened for subscription on July 14 and will close on July 16. It is expected to list on the Bombay Stock Exchange (BSE) and National Stock Exchange ( NSE) on July 21, 2025.

Anthem Biosciences IPO Subscription Details:

The IPO received bids for 14.51 crore shares against 4.17 crore shares on offer. Non-Institutional Investors (NIIs) led the way, subscribing 10.26 times their portion. The retail investor segment was subscribed 2.21 times, while Qualified Institutional Buyers (QIBs) lagged slightly at 62%.

Anthem Biosciences IPO GMP:

As of today, the grey market premium (GMP) for Anthem Biosciences IPO is Rs 142 at 5.37 PM, according to investorgain.com. This means investors are willing to pay Rs 142 more than the highest IPO price of Rs 570. Based on this, the estimated listing price of the shares could be around Rs 712, which is about 24.91% higher than the issue price.

Anthem Biosciences IPO Details:

The Anthem Biosciences IPO is fully an offer for sale, where existing shareholders are selling 5.96 crore shares, and the company is not issuing any new shares.

The allotment of shares is expected to be finalized on July 17, 2025, and the shares are likely to be listed on the BSE and NSE on July 21, 2025.

The price band for the IPO is set between Rs 540 and Rs 570 per share. Investors can apply in lots of 26 shares, which means the minimum investment for retail investors is Rs 14,040. There is also a special offer for employees, with 1,58,654 shares reserved at a Rs 50 discount per share.

JM Financial is managing the IPO, and KFin Technologies is the registrar.

About Anthem Biosciences:

Founded in 2006 and based in Bengaluru, Anthem is a global Contract Research, Development, and Manufacturing Organization (CRDMO). It offers end-to-end services across New Chemical Entities (NCEs) and New Biological Entities (NBEs). The firm specializes in complex, fermentation-based APIs like peptides, enzymes, and biosimilars.

In FY 2024-25, the company posted revenue of Rs 1,844.55 crore and a net profit of Rs 451 crore, with strong margins of 23.4%.

Should You Subscribe On The Last Day?

Brokerage firms are positive about the Anthem Biosciences IPO. Anand Rathi has given it a 'Subscribe' rating, saying the company has strong profits and good growth potential.

"Anthem Biosciences is a strong player in the CRO and CRDMO space, with high entry barriers due to its unique business model, long-term client relationships, and focus on R&D and innovation. The company has a solid profit track record and plans to grow by focusing on complex specialty products like peptides and probiotics. At a PE ratio of 70.6 based on FY25 earnings, the IPO is considered fairly priced. Given its growth potential, the recommendation is to subscribe to the IPO," mentioned Anandrathi.

Nirmal Banh also supports the IPO, highlighting that the company has built a strong global presence, backed by a significant level of expertise and the overall outlook is positive for the industry.

"Anthem Biosciences IPO is issued at a slightly lower valuation 71x to FY25 EPS when compared with its peers. However, we believe company's strong business model, focus on driving the growth adopting sustainability and historical robust financial performance to attract higher valuation in the future. Thus, we recommend SUBSCRIBE to the issue,: noted Nirmal Bang.

Deven Choksey Research mentioned that the IPO may be priced a bit high but still recommends it due to the company's strong profit margins and deep expertise in its field.

Disclaimer: The recommendations made above are by market analysts and are not advised by either the author, nor GoodReturns. The author, nor the brokerage firm nor GoodReturns would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.